Home>Media>News
> Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX (cabozantinib) ...
Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma
We use cookies to offer you a better experience on our site and analyze its audience. By continuing browsing, you accept the use OKMore information
YOU ARE ON THE SITE OF IPSEN GROUP
The corporate website of the Group is governed by the Code of Good Practices of the International Federation of Pharmaceutical Manufacturers Associations.
Certain information provided on the site may not be strictly applicable to your country of residence.
Usted está saliendo del sitio web ipsen.es. Este enlace le llevará a un sitio web en el que no se aplica nuestra Política de Privacidad. Usted es el único responsable de sus interacciones con ese sitio web.
You are now leaving the Ipsen Group website.
You are now leaving the Ipsen Group website. If you would like to visit an affiliate website, please click Continue. The information provided on this website may not necessarily be applicable to the Ipsen Group.
You are now leaving the Ipsen Group website. If you would like to visit an affiliate website (careers.ipsen.com), please click Continue.
You are now leaving the Ipsen Group website. If you would like to visit an affiliate website, please click Continue. The information provided on this website may not necessarily be applicable to the Ipsen Group.
